<--- Back to Details
First PageDocument Content
Medical physics / Biotechnology / Pharmaceutical industry / Pharmacology / Positron emission tomography / Microfluidics / Drug discovery / Radiopharmacology / Molecular imaging / Medicine / Pharmaceutical sciences / Radiation oncology
Date: 2012-08-22 04:18:47
Medical physics
Biotechnology
Pharmaceutical industry
Pharmacology
Positron emission tomography
Microfluidics
Drug discovery
Radiopharmacology
Molecular imaging
Medicine
Pharmaceutical sciences
Radiation oncology

Customer Profile “Establish in one day what traditionally takes weeks.” Vanderbilt University, Institute of Imaging Science Nashville, TN

Add to Reading List

Source URL: www.advion.com

Download Document from Source Website

File Size: 176,94 KB

Share Document on Facebook

Similar Documents

What Is PET? Positron Emission Tomography (PET) is a non-invasive form of medical imaging approved by Medicare for diagnosis and management of several forms of cancer including: 	 Lung Cancer

What Is PET? Positron Emission Tomography (PET) is a non-invasive form of medical imaging approved by Medicare for diagnosis and management of several forms of cancer including: Lung Cancer

DocID: 1uv0l - View Document

Determining the diagnostic kinetics of viral encephalitis using positron emission tomography (PET) in Münster Nicholas King, Discipline of Pathology, Bosch Institute, School of Medical Sciences, Sydney Medical School, U

Determining the diagnostic kinetics of viral encephalitis using positron emission tomography (PET) in Münster Nicholas King, Discipline of Pathology, Bosch Institute, School of Medical Sciences, Sydney Medical School, U

DocID: 1rQ7R - View Document

Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients. 89Zr-  Bernard M. Gburek1, Anthony

Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients. 89Zr- Bernard M. Gburek1, Anthony

DocID: 1rqYg - View Document

THE U~VERSITY OF NEW MEXICO COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO

THE U~VERSITY OF NEW MEXICO COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO

DocID: 1riLo - View Document

Microsoft Word - 25-32_FINAL_SN0302.doc

Microsoft Word - 25-32_FINAL_SN0302.doc

DocID: 1rbdW - View Document